Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Over 1 billion people, including 500 million children, in the poorest regions of the world, are affected by neglected diseases that debilitate, disfigure or kill.

DNDi’s research and development approach is driven by the real day-to-day needs of patients and healthcare providers.

By connecting public and private partners, DNDi synergizes expertise and capitalizes upon the best science. 

DNDi also works to strengthen the health R&D field in the countries where the diseases occur in order to reinforce capacities for sustainable change.

Major progress has been made with six new treatments made available since the creation of DNDi, in 2003. However, major breakthroughs are still needed to treat neglected patients: Entirely new, affordable, and adapted drugs will change the lives of millions of people.


New report on development of ASAQ

The antimalarial ASAQ is the first treatment delivered by DNDi and its partners. This new report summarises the key lessons learned. More

DNDi Unveils New Plan for Neglected Patients

In the new 2015-2023 business plan, DNDi presents its plans for a more flexible, dynamic portfolio approach to better respond to the needs of patients. DNDi aims to deliver 16-18 treatments for up to 10 diseases with EUR 650 million. More

Mycetoma: A Patient’s Struggle with a Neglected Disease

Eumycetoma is a chronic condition that affects people in tropical and subtropical regions. Nineteen years ago, while playing on the school field, Alsadik Mohamed Musa Omer pricked his foot on a thorn. More

DNDi 2014 Annual Report

Read DNDi's 2014 Annual Report: "Partnerships to Bridge Innovation and Access" More

Finding a Cure for Kala Azar

AlJazeera's The Cure travels travels to Japan, Switzerland and Ethiopia to explore how big pharmaceutical companies are being mobilised by DNDi in a new global initiative to find and fast-track a cure for kala-azar. More

Close-up on Chagas Disease

For Juan Bautista Corzo Veloza, a 53 year old, father of three, life is not the same since that day in January 2013 when a stroke left him "dead for three days," he says. More



September 6-10, 2015
9th European Congress on Tropical Medicine and International Health
DNDi presented in symposia and poster sessions on visceral leishmaniasis, open source
drug discovery, Chagas disease, helminth infections, sleeping sickness, ebola, and mycetoma.
Basel, Switzerland

October 15, 2015
DNDi India Stakeholders' Event: New R&D Pathways to Address
Neglected Patients` Needs in the Indian Subcontinent

New Delhi, India
DNDi India hosted a Stakeholders’ Event to launch DNDi `s new Business Plan, 2015-2023.

October 25-29, 2015
ASTMH 2015
American Society of Tropical Medicine and Hygiene (ASTMH), 64th Annual Meeting
Philadelphia, United States
DNDi participated in the 64th Annual Meeting of ASTMH.

November 23-25, 2016
IV Symposium on Drug Design and Development for Neglected Diseases
São Paulo, Brazil
Jean-Pierre Paccaud, Business Development Director of DNDi presented at this event.

See all events



DNDi Model Paper
DNDi has issued a report that explores the lessons learned from a decade of R&D of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model. Read more



Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License